COMMUNIQUÉS West-GlobeNewswire

Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome
03/01/2019
Meeting included representatives from NIH and BARDA HAIFA, Israel, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel [...]
Cabaletta Bio to Present at the 37th Annual J.P. Morgan Healthcare Conference
03/01/2019
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, today announced that [...]
Ultragenyx to Present at J.P. Morgan Healthcare Conference
03/01/2019
NOVATO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases [...]
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
03/01/2019
BOTHELL, WA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that [...]
Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence
03/01/2019
ENGLEWOOD, Colo., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it has completed enrollment in its LIBERATE- [...]
Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer
03/01/2019
Seasoned healthcare professional with over 20 years of strategic finance, capital markets and transactional/business-related expertise BEDMINSTER, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc [...]
United Soybean Board Awards Grant to Amfora to Increase the Protein Content of U.S. Soy
03/01/2019
Group’s focus on protein reflects effort to maintain U.S. soy farmers’ global market share SAN FRANCISCO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amfora, a biotechnology company that is applying gene editing to sustainably [...]
Obalon Announces Promotion of Amy VandenBerg to Chief Clinical & Regulatory Affairs Officer
03/01/2019
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric [...]
Allscripts to present at the J.P. Morgan 2019 Healthcare Conference
03/01/2019
CHICAGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX) today announced that certain members of its management team will present at the J.P. Morgan 2019 Healthcare Conference in San Francisco, CA on Monday [...]
EDAP TMS SA : John Wayne Cancer Institute First US Medical Center to Acquire EDAP's Breakthrough Focal One® Technology for Prostate Tissue Ablation
03/01/2019
Focal One System Enhances Precision Tissue Ablation, Reduces Side Effects for Prostate Cancer Patients LYON, France -- January 3, 2019 - EDAP TMS SA (Nasdaq: EDAP) today announced that the John Wayne Cancer Institute ( [...]
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
03/01/2019
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth [...]
Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
03/01/2019
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
03/01/2019
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two new medical [...]
Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer
03/01/2019
Phase 1 Data Expected the First Half of 2019 SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for SM08502 [...]
Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
03/01/2019
RP1: U.S. Enrollment Opened for Phase 1/2 Clinical Trial in Combination with Nivolumab in Patients with Solid Tumors RP1: Randomized Controlled Phase 2 Clinical Trial Alone and in Combination with Cemiplimab On Track to [...]
Fulgent Genetics and Columbia University Irving Medical Center Partner on Expanded Carrier Screening
03/01/2019
TEMPLE CITY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) and the Precision Genomics Laboratory (PGL), in collaboration with the Department of Obstetrics and Gynecology, at Columbia [...]
Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference
03/01/2019
BERKELEY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 37 [...]
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program
03/01/2019
Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program FDA pilot program is a 21 st Century Cures Act initiative CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. ( [...]
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
03/01/2019
Dose Escalation Trial in Patients with Solid Tumors CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of [...]

Pages